Elekta's Nomination Committee

Elekta's Nomination Committee

 

Press Release
Stockholm, Sweden, November 10, 2010

In accordance with the decision at the Annual General Meeting on
September 21, 2010, Elekta's Chairman of the Board has contacted the
company's largest shareholders to form a Nomination Committee.
Subsequently, the shareholders agreeing to participate in the work of
the Nomination Committee has each nominated a representative.
The Nomination Committee that will prepare matters prior to the Annual
General Meeting 2011 consists of Åsa Nisell, Swedbank Robur funds, Tove
Bångstad, Skandinaviska Enskilda Banken, Ole E. Dahl, Orkla ASA, Laurent
Leksell, representing his private and companies' holdings, and Akbar
Seddigh, Chairman of the Board. The Nomination Committee will appoint
one of the members as Chairman.
Combined, the shareholders in the Nomination Committee represented over
40 percent of the votes in Elekta AB on September 30, 2010.
Shareholders wishing to submit proposals to Elekta's Nomination
Committee can do so by e-mail at
valberedningen@elekta.com (valberedningen@elekta.com) or by letter to:
Elekta AB, Nomination Committee, Box 7593, SE-103 93 Stockholm, Sweden.
The Committee's assignment remains effective until a new Nomination
Committee is appointed.

# # # 

For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, +46 70 778 6010, email:
stina.thorman@elekta.com (stina.thorman@elekta.com) 

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy and radiosurgery, as well as workflow
enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both healthcare providers and patients, Elekta aims to improve, prolong
and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over
5,000 hospitals globally, and every day more than 100,000 patients
receive diagnosis, treatment or follow-up with the help of a solution
from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate
headquarter is located in Stockholm, Sweden, and the company is listed
on the Nordic Exchange under the ticker EKTAb. For more information
about Elekta, please visit www.elekta.com (http://www.elekta.com/).